Drugs / ABR-215050
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01048203 | Jan → Mar 2009 | — | Active Biotech AB | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00560482 Comparator | Dec 2007 → Jun 2010 | prostate cancer | Active Biotech AB | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABR-215050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00560482 ↗ |
| Known as | TASQ | “The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer...” PMID 21931019 ↗ Sep 2011 |
| Known as | tasquinimod | “The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer...” PMID 21931019 ↗ Sep 2011 |
| Route | Oral | “taken orally once daily” NCT00560482 ↗ |
| Target | S100A9 | “with S100A9 as a molecular target” PMID 21931019 ↗ Sep 2011 |